Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis

Jozef Hatok, Pavol Žúbor, Pavol Zubor, Silvester Galo, S Galo, Renata Kirschnerova, Dusan Dobrota, Dušan Dobrota, Ján Danko, Jan Danko, Peter Račay, Peter Racay
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2010 · vol. 27(5) , pp. 331–336 · doi:10.3109/09513590.2010.491925 · PMID:20553220 · W2066142960
article OA: closed CC0 ⤵ 19 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Endometrial aromatase mRNA expression was significantly increased in women with endometriosis and adenomyosis, particularly advanced stages, suggesting its potential as a screening tool.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis (ENDs) and adenomyosis (ADNs) are estrogen-dependent diseases. The aim of this study was to determine the clinical usefulness of examining endometrial biopsy specimens for aromatase cytochrome P450 (CYP19) as a diagnostic importance for endometriosis and adenomyosis. In general, the RT-PCR analyses of 101 samples revealed increased aromatase mRNA expression in eutopic endometrium in women with endometriosis and adenomyosis compared to healthy controls (p = 0.0002). The highest number of positive cases (93.3%) of CYP19 mRNA expression was detected in women with advanced disease stages. Concrete expression of CYP19 mRNA level in controls was 0.68 compared to patients with ADNs (1.21), ENDsL stage I-II (1.15) and ENDsA stage III-IV (1.65) (p < 0.0001), respectively. The possible influence of increased body mass index on aromatase expression in each group showed in controls an insignificant slight increase of aromatase expression, contrary to cases where this trend was the opposite. The results point to the higher (2.45-fold) difference in aromatase expression in patients with endometriosis stage III-IV compared to controls and provide direct evidence that screening for eutopic endometrial aromatase expression in combination with clinical data could be of discriminative value in the prediction of estrogen-dependent diseases, independent from body mass index.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisadenomyosis

MeSH descriptors

Aromatase Endometriosis Endometrium RNA, Messenger Adult Aromatase Aromatase Biopsy Body Mass Index Endometriosis Endometriosis Endometrium Female Humans Middle Aged Prognosis RNA, Messenger Severity of Illness Index Young Adult

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (26)

Cited by (19)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:17:07.008521+00:00
License: CC0 · commercial use OK